Savara (SVRA) Cash from Investing Activities (2010 - 2026)
Savara's (SVRA) quarterly Cash from Investing Activities came in at $38.8 million in Q1 2026, up 32.22% year-on-year from $29.3 million in Q1 2025, and up 141.45% on a QoQ basis from -$93.6 million in Q4 2025.
Savara (SVRA) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Savara (SVRA) has 17 years of Cash from Investing Activities data on file, last reported at $38.8 million in Q1 2026.
- On a quarterly basis, Cash from Investing Activities rose 32.22% year-over-year to $38.8 million in Q1 2026; TTM through Mar 2026 was -$9.0 million, a 58.0% increase from a year earlier, with the FY2025 full-year figure at -$18.4 million, up 53.83% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at $38.8 million, up from -$93.6 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for SVRA reached as high as $53.7 million in Q1 2022 and fell as low as -$98.2 million in Q3 2024.
- Historically, Cash from Investing Activities has averaged -$1.4 million across 5 years, with a median of $17.9 million in 2024.
- Across the five-year window, Cash from Investing Activities sank 4569.64% in 2022 and soared 3036.18% in 2024, its largest moves.
- Year by year, Cash from Investing Activities stood at -$59.2 million in 2022, then soared by 111.1% to $6.6 million in 2023, then soared by 172.33% to $17.9 million in 2024, then slumped by 622.85% to -$93.6 million in 2025, then soared by 141.45% to $38.8 million in 2026.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were $38.8 million in Q1 2026, -$93.6 million in Q4 2025, and $21.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 172.62 Mn |
| 10 | Savara | 1.39 Bn | 1.39 Bn | - | 38.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38.78 Mn |
| Mar 31, 2026 | 38.78 Mn |
| Dec 31, 2025 | -93.56 Mn |
| Dec 31, 2025 | -93.56 Mn |
| Sep 30, 2025 | 21.47 Mn |
| Sep 30, 2025 | 21.47 Mn |
| Jun 30, 2025 | 24.33 Mn |
| Jun 30, 2025 | 24.33 Mn |
| Mar 31, 2025 | 29.33 Mn |
| Mar 31, 2025 | 29.33 Mn |
| Dec 31, 2024 | 17.90 Mn |
| Dec 31, 2024 | 17.90 Mn |
| Sep 30, 2024 | -98.17 Mn |
| Sep 30, 2024 | -98.17 Mn |
| Jun 30, 2024 | 29.54 Mn |
| Jun 30, 2024 | 29.54 Mn |
| Mar 31, 2024 | 10.79 Mn |
| Mar 31, 2024 | 10.79 Mn |
| Dec 31, 2023 | 6.57 Mn |
| Dec 31, 2023 | 6.57 Mn |